Jeffrey A. Gelfand, MD
Dr. Gelfand is a Physician at MGH and Professor of Medicine, Part Time at Harvard Medical School. Dr. Gelfand has conducted laboratory and clinical research in immunology, inflammation and infection for over 40 years. Dr. Gelfand has focused on vaccines for infectious diseases and cancer. He initiated the programs on the ovarian cancer fusion- vaccine, self-assembling vaccine, and laser adjuvant that continue at the VIC. He has recently initiated funded studies on the uses of light energy as antimicrobial therapy and a strategy for overcoming antimicrobial resistance to antibiotics.
Before coming to MGH, he served as Dean for Research at Tufts University School of Medicine and Senior Vice President for Research and Technology at Tufts- New England Medical Center. From 1994 to 1998, Dr. Gelfand was Professor and Chairman of the Department of Medicine of Tufts University School of Medicine and Physician-in-Chief at Tufts- New England Medical Center. He has authored over 100 peer-reviewed papers and over 50 chapters in leading textbooks of Medicine and Infectious Diseases, and holds over a dozen US and international patents for medical advances. In 2008 he was elected a Fellow of the American Association for the Advancement of Science (AAAS) “for distinguished contributions to clinical immunology and vaccine development’’.
Outside of VIC
Dr. Gelfand is Chairman of the Partners Institutional Biosafety Committee; he is an Immunologist in the MGH Department of Surgery; on the Scientific Staff of the Shriners Hospital for Children-Boston and is Adjunct Faculty in the Wellman Center for Photomedicine. He has served as a Consultant and Program Director for the U.S. State Dept.